NNC0174-0833 · 10 mg / vial- ·3 mL bacteriostatic water
- ·10 × 1 mL insulin syringes
- ·Alcohol swabs
Cagrilintide 10 mg
Long-acting amylin analogue — GLP-1 stack partner.
Cagrilintide is a long-acting amylin analogue most widely investigated in combination with semaglutide under the CagriSema programme. Commonly stacked with GLP-1 receptor agonists in preclinical research.
What the peptide is.
Cagrilintide is a once-weekly amylin analogue developed by Novo Nordisk. Native amylin is a 37-residue pancreatic hormone co-secreted with insulin; its receptor activation slows gastric emptying, increases satiety, and modulates post-prandial glucagon.
Cagrilintide combines amylin-/calcitonin-receptor agonism with a long-acting pharmacokinetic profile via C20 fatty-diacid conjugation.
Agonism at calcitonin-family receptors (CT, AMY1, AMY2, AMY3). Slows gastric emptying, enhances satiety, modulates glucagon.
Reconstitution, storage, and handling.
Lab-technical guidance for the researcher handling the material. Not therapeutic dosing, not administration guidance — those are not within the scope of this supply.
- Recommended solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- Inject diluent slowly down the side of the vial onto the cake.
- Swirl gently — do not shake.
- Solution should be clear and colourless. Discard if not.
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life · sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
- Shelf life · reconstituted
- Up to 4 weeks refrigerated.
- ▸Amylin peptides are historically fibril-prone — handle gently, no vigorous agitation.
- ▸Clear to very slightly opalescent solution is typical.
This lot, documented.
Every shipment is accompanied by a signed four-page analytical report including the HPLC chromatogram, ESI-MS spectrum, purity calculation, and sample handling chain-of-custody.
The report you will receive is specific to the lot dispatched to you. The display below is a current representative example.
04:22:11▸lot 26-04-A received ┈ 5.00 g04:22:40▸weight check ┈ PASS ±0.4 mg04:23:12▸sample → janoshik ┈ 50 mg04:23:12▸tracking #jnk-921833405:18:03▸HPLC result ┈ 99.24 %05:18:04▸MS obs 4729.42 Da ┈ PASS05:18:05▸coa.pdf signed ┈ attached05:18:06▸lot approved ┈ LIVE
REPORT ID JA-26-04-012
SUBJECT Cagrilintide 10 mg
DESIGNATION NNC0174-0833
LOT 26-04-A
METHOD RP-HPLC, ESI-MS
COLUMN C18, 250 x 4.6 mm, 5 um
MOBILE PHASE A: 0.1% TFA in H2O
B: 0.1% TFA in ACN
GRADIENT 5 -> 65% B over 20 min
FLOW RATE 1.0 mL/min
DETECTION UV 214 nm
INJECTION 20 uL @ 0.5 mg/mL
---
PURITY (A%) 98.50
MASS EXP. 3906.50 Da
MASS OBS. 3906.52 Da
---
CONCLUSION Identity CONFIRMED · Purity PASS
SIGNED BY J. Novak, MSc · Janoshik Analytical SVK
DATE 2026-04-11Registered clinical investigation.
Links below resolve to the ClinicalTrials.gov registry. Trial status reflects publicly disclosed information at the time of publication.
| NCT | Phase | Title | Status | |
|---|---|---|---|---|
| NCT05567796 | Phase 3 | REDEFINE-1: CagriSema in obesity | Ongoing | Registry ↗ |
| NCT05813925 | Phase 3 | REDEFINE-2: CagriSema in obesity with T2D | Ongoing | Registry ↗ |
Research references for Cagrilintide 10 mg.
2 peer-reviewed publications. Links resolve to PubMed. DOIs are provided where available.
- [01]Enebo LB, et al.
Cagrilintide with semaglutide for weight management — Phase 1b
The Lancet · 2021 - [02]Lau DCW, et al.
Once-weekly cagrilintide for weight management — Phase 2
The Lancet · 2021
- Q.Can this be stacked with other peptides in a research protocol?
- A.Cagrilintide is most commonly paired with GLP-1 agonists in the published literature (the CagriSema programme). Each peptide is supplied separately; the decision to co-administer in a research protocol is the researcher's.
This peptide is supplied by Omega Grade for in vitro laboratory research use. It is not a drug, food, cosmetic, or dietary supplement. It is not approved by the FDA, EMA, MHRA, PMDA, or any other regulatory authority for any therapeutic indication.
No claim of therapeutic benefit is made or implied. The material is not intended for human or veterinary consumption, administration, or any form of self-experimentation. By purchasing, you acknowledge the researcher terms and accept full responsibility for local import compliance and all handling.
Often considered alongside.
Retatrutide 10 mg kit
Triple-receptor agonist — 10 mg vial, full research kit.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.2%
Retatrutide 30 mg kit
Triple-receptor agonist — 30 mg vial, full research kit.
- Form
- Lyophilised kit
- Dose
- 30 mg / vial
- Purity
- ≥ 99.2%